GlaxoSmithKline Stock News

GSK (GSK) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.09 per share a year ago.

High demand for the vaccine pulled in around $850 million during the third quarter—reportedly double what analysts were expecting—and GSK said annual sales could top $1 billion.

GSK PLC (LSE:GSK, NYSE:GSK) said a strong third quarter performance has driven a further upgrade to full-year guidance boosted by demand for its respiratory treatment in the US. The pharmaceuticals co

GSK raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on the strong launch of its respiratory syncytial virus (RSV) vaccine and steady demand for its

The company will for the first time report sales of Arexvy, its new RSV vaccine that launched this fall.

Pfizer , which dominated COVID vaccine sales, now finds itself looking up at GSK , whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this s

British drugmaker GSK said on Monday its cancer drug Jemperli met the primary goal of overall survival in patients with primary advanced or recurrent endometrial cancer in a late-stage trial.

One of the New York Yankees' most well-known players', Yogi Berra, famous for his strange, yet funny statements, used to say, “This is deja vu all over again.” That's how I feel about U.S. stocks

Strong sales of its shingles vaccine Shingrix has already seen GSK upgrade its forecasts for  2023. The pharmaceutical giant now expects turnover to increase by 8-10%, up from the previous estimate

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

The results suggest that GSK's shot could help protect a wider population from RSV, which causes thousands of hospitalizations and deaths each year.

GSK said they plan to submit data to regulators as soon as possible and expect a decision in 2024 on whether the shot, already approved for older adults, can be marketed towards people ages 50 to 59.

GSK PLC (LSE:GSK, NYSE:GSK) today unveiled ‘positive' preliminary results from the third phase of its trial of Arexvy, a vaccine against the potentially fatal respiratory syncytial virus (RSV) that�

British drugmaker GSK said on Wednesday its vaccine for respiratory syncytial virus (RSV) showed potential in a late-stage trial to help protect adults aged 50 to 59 years.

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive third-quarter sales performance.